false 0000718937 0000718937 2022-06-16 2022-06-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 16, 2022

 

 

STAAR Surgical Company

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

0-11634

95-3797439

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

25651 Atlantic Ocean Drive

Lake Forest, California

 

92630

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

STAA

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 



 

Item 5.07.

Submission of Matters to a Vote of Security Holders

STAAR Surgical Company’s virtual annual meeting of shareholders (the “Annual Meeting”) was held on June 16, 2022. 47,810,390 shares of common stock were outstanding on the record date for the Annual Meeting (April 19, 2022) and entitled to vote at the Annual Meeting.  The voting was as follows:  

1.

To elect seven directors to serve for terms to expire in 2023 or until their successors have been elected and qualified.  

 

Number of Shares

For

Withheld

Broker Non-Votes

Stephen C. Farrell

38,686,846

950,903

2,821,894

Thomas G. Frinzi

Gilbert H. Kliman, MD

Caren Mason

39,152,758

29,360,877

39,575,413

484,991

10,276,872

62,336

2,821,894

2,821,894

2,821,894

Aimee S. Weisner

38,340,441

1,297,308

2,821,894

Elizabeth Yeu, MD

39,155,168

482,581

2,821,894

K. Peony Yu, MD

39,161,655

476,094

2,821,894

 

 

 

 

 

 

 

 

2.  

To ratify the selection of BDO USA, LLP as the Company’s independent registered public accountants for the fiscal year ending December 30, 2022.  

 

Number of Shares

For

Against

Abstain

41,529,420

888,589

41,634

 

3.

To approve an increase in the annual equity award to non-employee directors.  

 

Number of Shares

For

Against

Abstain

Broker Non-Votes

39,098,595

508,699

30,455

2,821,894

 

 

 


 

4.

To hold an advisory vote to approve STAAR’s compensation of its named executive officers.  

 

Number of Shares

For

Against

Abstain

Broker Non-Votes

37,903,986

1,514,494

219,269

2,821,894

 

 

After the Annual Meeting, the Board of Directors appointed Mr. Frinzi as Chair of the Board of Directors, Mr. Farrell as Chair of the Audit Committee, Mr. Frinzi as Chair of the Compensation Committee, and Ms. Weisner as Chair of the Nominating and Governance Committee.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STAAR Surgical Company, 

 

June 17, 2022

By:

/s/ Caren Mason

 

 

Caren Mason

 

 

President and Chief Executive Officer